All they would need to do is establish what the receptor occupancy is at each dose level and whether that increased receptor occupancy correlates with increased efficacy at each dose level from the combo therapy trial. For 700mg I believe they would have to pull efficacy from the CD02 extension trial. Since the approval is for combo therapy viral loads from monotherapy would be irrelevant. The only thing they would need from the monotherapy trial would be the safety data.